OncoEthix brings in CHF18m to push ex-Mitsubishi candidate
This article was originally published in Scrip
OncoEthix, a Swiss-based biotech firm focused on drug development in oncology, has closed a series B financing which raised CHF18m (around $19m). SV Life Sciences (SVLS) led the financing, joined by new investor Edmond de Rothschild Investment Partners. Existing investors including Index Ventures and Endeavour Vision also participated.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.